Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a publicly traded Healthcare sector company. As of July 11, 2026, CTNM trades at $15.08 with a market cap of $577.62M and a P/E ratio of -6.96. CTNM moved -1.68% today. Year to date, CTNM is +32.90%; over the trailing twelve months it is +276.92%. Its 52-week range spans $3.35 to $17.49. Analyst consensus is strong buy with an average price target of $21.20. Rallies surfaces CTNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for CTNM combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $15.08 |
| Market Cap | $577.62M |
| P/E Ratio | -6.96 |
| EPS | $-2.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.49 |
| 52-Week Low | $3.35 |
| Volume | 255.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-59.98M |
| Gross Margin | 0.00% |
5 analysts cover CTNM: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.20.